Autonomix Medical, Inc（AMIX）财务数据AMIXAutonomix Medical, Inc

Evaluating the bottom line, Autonomix Medical, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -315.99%, provide a clear picture of how effectively AMIX converts its operational activities into shareholder value.

In the context of the broader market, AMIX competes directly with industry leaders such as BDMD and VVOS. With a market capitalization of $2.94M, it holds a leading position in the sector. When comparing efficiency, AMIX's gross margin of N/A stands against BDMD's 86.97% and VVOS's 47.41%. Such benchmarking helps identify whether Autonomix Medical, Inc is trading at a premium or discount relative to its financial performance.

Autonomix Medical has not generated any revenue in several recent quarters, with total revenue reported at 0.00 USD for Q1, Q2, and Q3 of 2026. The company continues to incur substantial losses, with a net income loss of -7,451,000 USD in Q2 2026 and a gross profit of -3,000 USD in Q4 2026.